Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WCNDD ROCK2 inhibitor
- Development stage
- Preclinical
- Lead developer
- Warren Center for Neuroscience Drug Discovery
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The WCNDD ROCK2 inhibitor program is a small-molecule drug discovery initiative developed by the Warren Center for Neuroscience Drug Discovery (WCNDD) at Vanderbilt University. The program focuses on the development of potent and selective inhibitors of Rho-associated protein kinase 2 (ROCK2), a serine/threonine kinase that serves as a key effector of the RhoA GTPase. ROCK2 is a critical regulator of the actin cytoskeleton, cell polarity, and migration. In neurodegenerative research, ROCK2 inhibition is being investigated for its potential to protect dopaminergic neurons in Parkinson's Disease (PD) by reducing alpha-synuclein aggregation and mitigating neuroinflammation. In oncology, the program targets the role of ROCK2 in promoting the epithelial-mesenchymal transition (EMT), invasion, and metastasis in cancers such as prostate and ovarian cancer. The program is currently in the IND-enabling phase, with candidates being prepared for clinical evaluation.
- Other names
- Warren Center for Neuroscience Drug Discovery ROCK2 inhibitorROCK2 (Rho-associated protein kinase 2) programWCNDD ROCK2 program
02
Targets
ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on WCNDD ROCK2 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WCNDD ROCK2 inhibitor.